ClinVar Miner

Submissions for variant NM_000249.3(MLH1):c.1409+1G>A (rs267607825)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
International Society for Gastrointestinal Hereditary Tumours (InSiGHT) RCV000075192 SCV000106182 likely pathogenic Lynch syndrome 2019-06-21 reviewed by expert panel curation Interrupts canonical donor splice site
Ambry Genetics RCV000220831 SCV000276156 pathogenic Hereditary cancer-predisposing syndrome 2018-03-20 criteria provided, single submitter clinical testing Lines of evidence used in support of classification: Alterations at the canonical donor/acceptor sites (+/- 1, 2) without other strong (B-level) evidence supporting pathogenicity,Detected in individual satisfying established diagnostic critera for classic disease without a clear mutation
Invitae RCV000524237 SCV000543606 pathogenic Hereditary nonpolyposis colon cancer 2018-11-21 criteria provided, single submitter clinical testing This sequence change affects a donor splice site in intron 12 of the MLH1 gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product. This variant has been reported in the literature in a family with suspected Lynch syndrome (PMID: 17348456). ClinVar contains an entry for this variant (Variation ID: 89718). A different variant affecting this nucleotide (c.1409+1G>C) has been determined to be pathogenic (PMID: 10200055, 12362047, 9322509, 14574010, 16451135). This suggests that this nucleotide is important for normal RNA splicing, and that other variants at this position may also be pathogenic. For these reasons, this variant has been classified as Pathogenic.
GeneDx RCV000519388 SCV000617551 pathogenic not provided 2017-07-20 criteria provided, single submitter clinical testing This variant is denoted MLH1 c.1409+1G>A or IVS12+1G>A and consists of a G>A nucleotidesubstitution at the +1 position of intron 12 of the MLH1 gene. This variant destroys a canonical splice donor site and ispredicted to cause abnormal gene splicing, leading to either an abnormal message that is subject to nonsense-mediated mRNA decay or to an abnormal protein product. This variant has been reported in at least one family withuterine and colorectal cancer (Irmejs 2007) and an alternate change, MLH1 c.1409+1G>C, has been observed in atleast one family meeting Amsterdam Criteria for Lynch syndrome (Peltomäki 1997, Kurzawski 2002). Based on thecurrent evidence, we consider MLH1 c.1409+1G>A to be pathogenic.
Integrated Genetics/Laboratory Corporation of America RCV000075192 SCV000696109 likely pathogenic Lynch syndrome 2017-07-12 criteria provided, single submitter clinical testing Variant summary: The MLH1 c.1409+1G>A variant involves the alteration of a non-conserved intronic nucleotide that 5/5 splice prediction tools predict a the elimination of a canonical 5' splice donor site. However, these predictions have yet to be confirmed by functional studies. This variant is absent in 120470 control chromosomes. A publication cites the variant in an affected individual. In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as likely pathogenic. Taken together, this variant is classified as likely pathogenic.
GeneKor MSA RCV000519388 SCV000821733 likely pathogenic not provided 2018-08-01 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.